| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/08/2004 | US20040006778 Comprises heat resistant polypeptide for preparing pharmaceuticals; drug biosynthesis; side effect reduction |
| 01/08/2004 | US20040006777 Comprises nucleotide sequences coding cytoplasmic phosphatases for treating and preventing tumors and metastasis; immunosuppressant |
| 01/08/2004 | US20040006230 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
| 01/08/2004 | US20040006220 Antisense modulation of insulin-like growth factor 2 expression |
| 01/08/2004 | US20040006217 Comprises coagulation factor VIIa/VII receptor for treatment and prevention of thrombosis, septic shock and adult respiratory distress syndrome (ARDS); anticoagulants; thrombolytic agents |
| 01/08/2004 | US20040006216 Comprises immunoglobulin for treating cancer; immunosuppressant; immunotherapy |
| 01/08/2004 | US20040006213 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use |
| 01/08/2004 | US20040006212 Antibody and antibody fragments for inhibiting the growth of tumors |
| 01/08/2004 | US20040006210 Human polyhomeotic 2 (hph2) acts as an oncogene |
| 01/08/2004 | US20040006207 Comprises ligand polypeptide for treatment of viral infection and prevention of immunological response; immunosuppressants; genetic vaccines |
| 01/08/2004 | US20040006205 Comprises g-protein coupled receptor polypeptides for diagnosis, prevention and treatment of cancers, infections and dyslipidemias |
| 01/08/2004 | US20040006202 Comprises tyrosine phosphatase peptides for diagnosis, prevention and treatment of autoimmune diseases; immunotherapy |
| 01/08/2004 | US20040006132 For therapy |
| 01/08/2004 | US20040006093 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 01/08/2004 | US20040006087 Method of treating cancer using FPT inhibitors and antineoplastic agents |
| 01/08/2004 | US20040006067 Substituted piperidines and methods of use |
| 01/08/2004 | US20040006063 Dipeptide derivatives |
| 01/08/2004 | US20040006049 For therapy of prostatitis, benign prostate hyperplasia or prostate cancer |
| 01/08/2004 | US20040006043 Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents |
| 01/08/2004 | US20040006039 Neutral sphingomyelinase antisense ribozyme and uses thereof |
| 01/08/2004 | US20040006038 Method for therapy of rheumatoid arthritis |
| 01/08/2004 | US20040006035 For modulating HIV cell fusion activity in a cell |
| 01/08/2004 | US20040006031 For therapy of disease or condition such as cholesterol metabolism, cardiovascular disease, atherosclerosis, angiogenesis |
| 01/08/2004 | US20040006030 For therapy of hyperproliferative disorder, hyperactivation of an immune response, neurodegenerative disorder |
| 01/08/2004 | US20040006029 Antisense modulation of cell division cycle 2 expression |
| 01/08/2004 | US20040006024 Therapy of vaginitis by administering a polypeptide including an amino acid sequence KPV(lysine-proline-valine) at C-terminus |
| 01/08/2004 | US20040006022 For therapy of autoimmune or an inflammatory disease |
| 01/08/2004 | US20040006021 Pharmaceutical composition comprising factor Vll polypeptides and tranexamic acid |
| 01/08/2004 | US20040006020 Pharmaceutical composition comprising a factor VII polypeptide and epsilon-aminocaproic acid |
| 01/08/2004 | US20040006018 Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFR beta . These CT-1 molecules are shown to influence hypertrophic activity, |
| 01/08/2004 | US20040006017 Administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering |
| 01/08/2004 | US20040006016 Isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors and fusion proteins |
| 01/08/2004 | US20040006015 Treatment of inflammatory bowel disease using growth factors |
| 01/08/2004 | US20040006014 Administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index |
| 01/08/2004 | US20040006013 Linear and cyclic peptide and pseudopeptide compounds useful as analgesics, pharmaceutical compositions comprising such compounds, the use of the compounds and the compositions in the treatment of pain, and commercial packages containing such |
| 01/08/2004 | US20040006012 Microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant |
| 01/08/2004 | US20040006011 Peptidomimetic modulators of cell adhesion |
| 01/08/2004 | US20040006010 Compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the |
| 01/08/2004 | US20040006009 Pharmaceutical compositions comprising mannose binding lectin |
| 01/08/2004 | US20040006008 Localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper |
| 01/08/2004 | US20040006006 Polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the |
| 01/08/2004 | US20040006005 Treating conditions of insulin resistance, hyperglycemia and/or diabetes. In a broad embodiment, the methods comprise the step of administering to a mammal in need of treatment a therapeutically effective amount of an ILK inhibitor. |
| 01/08/2004 | US20040006004 This invention concerns a method for treating or preventing a disease or disorder related to excessive formation of vascular tissue or blood vessels in a patient, said method comprising administering to said patient an agent affecting the NPY Y2 |
| 01/08/2004 | US20040006003 Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| 01/08/2004 | US20040006002 Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
| 01/08/2004 | US20040006001 Ferritin fusion proteins for use in vaccines and other applications |
| 01/08/2004 | US20040006000 Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog. A soluble formulation comprising (i) a soluble acylated insulin analogue and (ii) a monomeric insulin or human insulin |
| 01/08/2004 | US20040005999 Sustained release preparations of insulin comprising polyamino acid particles, insulin and one or more preservative agents, and a method of preparing such preparations. |
| 01/08/2004 | US20040005997 Screening methods for identifying compounds that bind to or activate amylin receptors (AR) and regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that |
| 01/08/2004 | US20040005996 Method of producing protein stabilised emulsions comprising the steps of decreasing the pH of a protein solution by the addition of an acidic solution to convert it to a cationic form, heating the solution until the protein is solubilised, |
| 01/08/2004 | US20040005707 Antisense modulation of integrin beta 5 expression |
| 01/08/2004 | US20040005706 Antisense modulation of DEXRAS1 expression |
| 01/08/2004 | US20040005705 Comprises oligonucleotides for controlling expression of phospholipase D2 and treating cancer and nervous system disorders; gene expression inhibition; antisense therapy |
| 01/08/2004 | US20040005704 Propagating neuronal cells in reduced oxygen environment for treating parkinson's and neurodegenerative diseases; in vitro culture and cell differentiation/proliferation; gene therapy; tissue engineering; antiapoptosis |
| 01/08/2004 | US20040005701 Using trophoblast inducing factor to differentiate primate stem cells into trophoblast; tissue engineering; cell differentiation/proliferation |
| 01/08/2004 | US20040005688 Comprises dishevelled associated kinase (DAK) protein for diagnosis, prevention and treatment of cell proliferative diseases |
| 01/08/2004 | US20040005684 Targeting proteins to deliver therapeutic or diagnostic reagents |
| 01/08/2004 | US20040005670 Compositions and methods for the treatment of hemophilia A |
| 01/08/2004 | US20040005668 Production of human parathyroid hormone from microorganisms |
| 01/08/2004 | US20040005667 Comprises protein for developing vaccines which prevent chlamydial infections; genetic vaccines |
| 01/08/2004 | US20040005666 Methods and reagents for modulating cholesterol levels |
| 01/08/2004 | US20040005664 Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor |
| 01/08/2004 | US20040005661 Comprises mitogenic factor for propagation neuronal cells and treating nervous system disorders |
| 01/08/2004 | US20040005658 Embryonic protein for diagnosis, prevention and treatment of tumors, blood, viral and immunological disorders |
| 01/08/2004 | US20040005656 Novel GPCR-like proteins and nucleic acids encoding same |
| 01/08/2004 | US20040005654 Method of producing polyvalent antigens |
| 01/08/2004 | US20040005643 Anti-human tenascin monoclonal antibody |
| 01/08/2004 | US20040005630 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 01/08/2004 | US20040005626 Comprises nucleotide sequences coding membrane protein for diagnosing and treating inflammatory and tumor disorders |
| 01/08/2004 | US20040005603 Gene shinc-3 and diagnostic and therapeutic uses thereof |
| 01/08/2004 | US20040005602 DNA encoding the vertebrate homolog of hedgehog, Vhh-1, expressed by the notocord, and uses thereof |
| 01/08/2004 | US20040005601 Identifying modulators of quadruplex DNA activity; drug delivery; cancer diagnosis; antitumor agents |
| 01/08/2004 | US20040005598 Comprises nucleotide sequences coding protein upregulated in metastatic prostate cancer (PUMPCn) for diagnosis and treatment of tumors; antiproliferative agents; anticarcinogenic agents |
| 01/08/2004 | US20040005592 Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides |
| 01/08/2004 | US20040005590 Isolated human RAS-like proteins, nucleic acid molecules encoding these human RAS-like proteins, and uses thereof |
| 01/08/2004 | US20040005588 Using DNA vaccines to treat and prevent insulin depentent diabetes mellitus |
| 01/08/2004 | US20040005581 Comprises nucleotide sequences coding vanilloid receptor-like receptor (VR4) for diagnosing and treating pain, inflammation, neurodegeneration, cardiovascular, cancer and urogenital diseases; drug screening |
| 01/08/2004 | US20040005579 Nucleic acids, proteins, and antibodies |
| 01/08/2004 | US20040005578 Myocardial cell proliferation-associated genes |
| 01/08/2004 | US20040005577 Nucleic acids, proteins, and antibodies |
| 01/08/2004 | US20040005576 Comprises polypeptides for diagnosing, prognosing and preventing cancer, nervous system, developmental and metabolic disorders |
| 01/08/2004 | US20040005575 Nucleic acids, proteins, and antibodies |
| 01/08/2004 | US20040005570 Oligonucleotides which control expression of geranylgeranyl diphosphate synthase for treating tumors, apoptosis aberrations and developmental disorders; gene expression inhibition; antisense therapy |
| 01/08/2004 | US20040005569 Antisense modulation of NF-kappa-B p50 subunit expression |
| 01/08/2004 | US20040005567 Antisense modulation of cyclin-dependent kinase 4 expression |
| 01/08/2004 | US20040005565 Antisense modulation of livin expression |
| 01/08/2004 | US20040005561 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 01/08/2004 | US20040005558 Proteins, polynucleotides ecoding them and methods of using the same |
| 01/08/2004 | US20040005557 Comprises polypeptide for diagnosing and treating inflammatory, nervous system, autoimmune and infectious disorders |
| 01/08/2004 | US20040005554 Novel glycoproteins and methods of use thereof |
| 01/08/2004 | US20040005553 Comprises membrane protein for treating cancer, inflammation and autoimmune disorders |
| 01/08/2004 | US20040005550 Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3 |
| 01/08/2004 | US20040005539 Comprises expression vector coding antibody domains and heterologous proteins for use as model in design of improved binding domains; enzyme inhibitors |
| 01/08/2004 | US20040005537 Method of identifying toxic agents using differential gene expression |
| 01/08/2004 | US20040005365 Carcinostatic substance for compatible administration, process of administrating same and process of rapidly inspecting same |
| 01/08/2004 | US20040005353 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is |
| 01/08/2004 | US20040005334 Redirection of cellular immunity by receptor chimeras |
| 01/08/2004 | US20040005331 Polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for |
| 01/08/2004 | US20040005329 Methods for inhibiting tumor cell growth, or treating cancer cells, in a subject through the administration of a cathepsin inhibitor or inhibitors. Methods for inhibiting inflammatory disease cells as well as cathepsin expressing cells in a |
| 01/08/2004 | US20040005328 Novel antigens of B. catarrhalis are provided, together with their use in vaccines as well as methods of diagnosing and/or detection. Branhamella catarrhalis (also known as Moraxella catarrhalis) is a gram-negative aerobic bacterium that causes |